Meeting
2018 Gastrointestinal Cancers Symposium
Prospective multicenter study of the impact of the 12-gene assay recurrence score on adjuvant chemotherapy treatment recommendations for stage II/III colon cancer in the post-IDEA era: SUNRISE-Decision Impact study.
Authors
Takeharu Yamanaka
Yokohama City University, Yokohama, Japan
Takeharu Yamanaka , Takeo Sato , Sayoko Nakashima , Takayuki Yoshino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr TPS868)
DOI
10.1200/JCO.2018.36.4_suppl.TPS868
Abstract #
TPS868
Poster Bd #
P20
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.
First Author: Anthony Frank Shields
Poster
2012 Gastrointestinal Cancers Symposium
Comparative effectiveness of treatment options in elderly patients with colon cancer receiving adjuvant chemotherapy.
First Author: Sacha Satram-Hoang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world evidence of FOLFIRI combined with anti-angiogenesis inhibitors or anti-EGFR antibodies for patients with early recurrence colorectal cancer after adjuvant FOLFOX/CAPOX therapy in Japan: A retrospective observational study using administrative database.
First Author: Yu Sunakawa
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Changes in prescribing patterns in stage III colon cancer (CC) since the IDEA collaboration.
First Author: Daniel Walden